Ionis to present at 41st Annual J.P. Morgan Healthcare conference
Get Alerts IONS Hot Sheet
Join SI Premium – FREE
CARLSBAD, Calif., Jan. 4, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Brett P. Monia, Ph.D., chief executive officer, will present a company overview and participate in a Q&A session at the 41st Annual J.P. Morgan Healthcare Conference at 9:45 a.m. PT (12:45 p.m. ET) on Wednesday, January 11, 2023.
A live webcast of the presentation and Q&A session will be available on the Investors & Media section of the Ionis website. The replay will be available within 48 hours and will be archived for a limited time.
For more than 30 years, Ionis has been the leader in RNA-targeted therapy, pioneering new markets and changing standards of care with its novel antisense technology. Ionis currently has three marketed medicines and a premier late-stage pipeline highlighted by industry-leading cardiovascular and neurological franchises. Our scientific innovation began and continues with the knowledge that sick people depend on us, which fuels our vision of becoming a leading, fully integrated biotechnology company.
To learn more about Ionis visit www.ionispharma.com and follow us on Twitter @ionispharma.
View original content to download multimedia:https://www.prnewswire.com/news-releases/ionis-to-present-at-41st-annual-jp-morgan-healthcare-conference-301712823.html
SOURCE Ionis Pharmaceuticals, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Amwell Receives Frost & Sullivan's 2026 United States Technology Innovation Leadership Recognition for Technology-Enabled Care Platforms
- ErieView Development Closes $218 Million in Financing for W Cleveland at Erieview Tower
- Can AI Really Predict The Next Car Breakdown? THINKCAR’s Tyler Turns Patterns Into Early Warnings
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
JPMorgan, TwitterSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share